Acute Myeloid Leukemia, Version 2.2013

Key Points

Key points are not available for this paper at this time.

Abstract

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL.

Bookmark

View Full Paper

Cite This Study

O’Donnell et al. (Sun,) studied this question.

synapsesocial.com/papers/6a22bbfad60c1884c1d2c032 https://doi.org/https://doi.org/10.6004/jnccn.2013.0127

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia2013 · 1,606 citations
2Acute Myeloid Leukemia with Recurrent Genetic Abnormalities2021 · 20 citations
3Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group2010 · 16 citations
4Acute Myeloid Leukemia with Recurrent Genetic Abnormalities2014 · 73 citations
5Very Long Term Outcome of Acute Promyelocytic Leukemia After Treatment with All Trans Retinoic Acid and Chemotherapy: The European APL Group Experience.2009 · 22 citations

Bookmark

View Full Paper